Skip to main content

Advertisement

SpringerLink
Log in

Serum Adenosine deaminase activity in type 2 Diabetes Mellitus patients

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

The assessment of insulin resistance is advantageous since it detects those at risk for the development of diabetes mellitus at early stages and minimizes complications. Various methods like euglycemic hyperinsulinemic clamp technique, fasting serum insulin levels, HOMA and QUICKI have been used to determine insulin sensitivity but they have limitations. Adenosine deaminase (ADA) is an enzyme that has been suggested to be important for modulating the bioactivity of insulin. The aim of this study was to determine the activity of serum adenosine deaminase (ADA) in patients of type 2 diabetes mellitus and to evaluate the role of serum adenosine deaminase as a marker for insulin resistance. The study recruited 46 subjects of Type 2 diabetes mellitus and 40 healthy controls matched for age and sex between May 2010 and November 2010. Fasting serum glucose, insulin, adenosine deaminase activity were estimated. QUICKI and HOMA were calculated. Serum ADA was positively correlated with fasting serum glucose, insulin, HOMA and negatively correlated with QUICKI in the diabetic group. At 95 % CI and a cut off of 36.91U/L serum ADA activity in the diabetic group showed a sensitivity and specificity of 98 % and 90 % respectively. Serum ADA activity was increased with an increase in insulin resistance in the diabetic population. ADA may be used as a marker of insulin resistance and can be employed as an effective tool in screening for insulin resistance and diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1:S62–7.

    Article  Google Scholar 

  2. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:S5–20.

    Google Scholar 

  3. Potenza MV, Mechanick JI. The metabolic syndrome: definition, global impact, and pathophysiology. Nutr Clin Pract. 2009;24:560–77.

    Article  PubMed  Google Scholar 

  4. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888–904.

    Article  PubMed  Google Scholar 

  5. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231–7.

    Article  CAS  Google Scholar 

  6. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:15–26.

    Article  Google Scholar 

  7. Borai A, Livingstone C, Ferns GAA. The biochemical assessment of insulin resistance. Ann Clin Biochem. 2007;44:324–42.

    Article  PubMed  CAS  Google Scholar 

  8. Edwards YH, Hopkanson DA, Hams H. Adenosme deaminase lsozymes in human tissues. Ann Hum Genet. 1971;35:207–18.

    Article  PubMed  CAS  Google Scholar 

  9. Van der Weyden MB, Kelly WN. Human adenosine deaminase: distribution and properties. J Biol Chem. 1976;251:5448–56.

    PubMed  Google Scholar 

  10. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol. 2005;86:1–41.

    Article  PubMed  CAS  Google Scholar 

  11. Baghanha MF, Pego A, Lima MA, et al. Serum and pleural adenosine deaminase correlation with lymphocyte populations. Chest. 1990;87:605–10.

    Article  Google Scholar 

  12. Ungerer JP, Oosthuizen HM, Bissbort SH, Vermaak WJ. Serum adenosine deaminase: isoenzymes and diagnostic application. Clin Chem. 1992;38:1322–6.

    PubMed  CAS  Google Scholar 

  13. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 2009;16:2943–51.

    Article  PubMed  CAS  Google Scholar 

  14. Kurtul N, Pence S, Akarsu E, et al. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica(Hradec Kralove). 2004;47:33–5.

    CAS  Google Scholar 

  15. Hoshino T, Yamada K, Masuoka K, et al. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Res Clin Pract. 1994;25:97–102.

    Article  PubMed  CAS  Google Scholar 

  16. Warrier A, Rao NY, et al. Evaluation of Adenosine Deaminase activity and lipid peroxidation levels in Diabetes Mellitus. IJCB. 1995;10:9–13.

    Google Scholar 

  17. Rutkiewicz J, Gorski J. On the role of insulin in regulation of adenosine deaminase activity in rat tissues. FEBS Lett. 1990;271:79–80.

    Article  PubMed  CAS  Google Scholar 

  18. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460–4.

    Article  PubMed  CAS  Google Scholar 

  19. Gupta A, Gupta V, Agrawal S, Natu SM, Agrawal CG, Negi MPS, Tiwari S. Association between circulating leptin and insulin resistance, the lipid profile, and metabolic risk factors in North Indian adult women. BioScience Trends. 2010;4:325–32.

    PubMed  CAS  Google Scholar 

  20. Giusti G, Galanti B. Colorimetric method. Adenosine deaminase. In: Bergmeyer HU, editor. Methods of enzymatic Analysis. 3rd ed. Weinheim: Verlag chemie; 1984. p. 315–23.

    Google Scholar 

  21. Lee JG, Kang DG, Yu JR, Kim Y, Kim J, Koh G, et al. Changes in adenosine deaminase activity in patients with type 2 diabetes mellitus and effect of DPP-4 inhibitor treatment on ADA activity. Diabetes Metab J. 2011;35:149–58.

    Article  PubMed  CAS  Google Scholar 

  22. Bottini E, Gloria-Bottini F. Adenosine deaminase and body mass index in non-insulin-dependent diabetes mellitus. Metabolism. 1999;48:949–51.

    Article  PubMed  CAS  Google Scholar 

  23. Bopp A, De Bona KS, Bellé LP, Moresco RN, Moretto MB. Syzygium cumini inhibits adenosine deaminase activity and reduces glucose levels in hyperglycemic patients. Fundam Clin Pharmacol. 2009;23:501–7.

    Article  PubMed  CAS  Google Scholar 

  24. Koopmans SJ, Sips HC, Bosman J, Radder JK, Krans HM. Antilipolytic action of insulin in adipocytes from starved and diabetic rats during adenosine-controlled incubations. Endocrinology. 1989;125:3044–50.

    Article  PubMed  CAS  Google Scholar 

  25. Green A, Newsholme EA. Sensitivity of glucose uptake and lipolysis of white adipocytes of the rat to insulin and effects of some metabolites. Biochem J. 1979;180:365–70.

    PubMed  CAS  Google Scholar 

  26. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51:2074–81.

    Article  PubMed  CAS  Google Scholar 

  27. Pérez-Aguilar MC, Goncalves L, Ibarra A, Bonfante-Cabarcas R. Adenosine deaminase as costimulatory molecule and marker of cellular immunity. Investig Clin. 2010;51:561–71.

    Google Scholar 

  28. Lambeir AM, Durinx C, Scharpé S, De Meester I, Dipeptidyl-peptidase IV. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Sciences. 2003;40:209–94.

    CAS  Google Scholar 

  29. Gracia E, Pérez-Capote K, Moreno E, Barkešová J, Mallol J, Lluís C, et al. A2A adenosine receptor ligand binding and signalling is allosterically modulated by adenosine deaminase. Biochem J. 2011;435:701–9.

    Article  PubMed  CAS  Google Scholar 

  30. Samsel M, Dzierzbicka K. Therapeutic potential of adenosine analogues and conjugates. Pharmacol Rep Online. 2011;63:601–17.

    CAS  Google Scholar 

  31. Kaya S, Cetin ES, Aridogan BC, Arikan S, Demirci M. Adenosine deaminase activity in serum of patients with hepatitis—a useful tool in monitoring clinical status. J Microbiol Immunol Infect. 2007;40:288–92.

    PubMed  CAS  Google Scholar 

  32. Kobayashi F, Ikeda T, Marumo F, Sato C. Adenosine deaminase isoenzymes in liver disease. Am J Gastroenterol. 1993;88:266–71.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, MS Ramaiah Medical College, MSR Nagar, MSRIT Post, Bangalore, 560054, India

    M. N. Vanitha Gowda, K. C. Vasudha, S. Reshma & K. J. Sujatha

Authors
  1. M. N. Vanitha Gowda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. C. Vasudha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Reshma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. J. Sujatha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. N. Vanitha Gowda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gowda, M.N.V., Vasudha, K.C., Reshma, S. et al. Serum Adenosine deaminase activity in type 2 Diabetes Mellitus patients. Int J Diabetes Dev Ctries 32, 176–181 (2012). https://doi.org/10.1007/s13410-012-0087-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-012-0087-x

Keywords

Search

Navigation